Aldeyra Therapeutics Inc. [NASDAQ: ALDX] loss -2.62% on the last trading session, reaching $6.33 price per share at the time. The company report on July 14, 2020 that Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners.
Gross Proceeds of Approximately $19.5 Million from At-the-Market Offering Program Sufficient to Extend Operations Through the End of 2022, Including Potential New Drug Application (NDA) Approvals for Reproxalap in Dry Eye Disease and Allergic Conjunctivitis, Based on Current Operating Plans.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced block sales of an aggregate of 4,580,361 shares of common stock to Perceptive Advisors, LLC and Avidity Partners Management LP, two leading healthcare-focused investment funds, under Aldeyra’s previously announced at-the-market offering program. The shares were sold for a price of $4.25 per share. Aggregate gross proceeds, before deducting commissions, were approximately $19.5 million. The sales completed Aldeyra’s previously disclosed at-the-market offering program and no further sales will be made under this program. Jefferies, LLC served as sales agent under the at-the-market offering program.
Aldeyra Therapeutics Inc. represents 29.21 million in outstanding shares, while the company has a total market value of $171.04 million with the latest information. ALDX stock price has been found in the range of $6.085 to $6.68.
If compared to the average trading volume of 1.39M shares, ALDX reached a trading volume of 1189766 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Aldeyra Therapeutics Inc. [ALDX]:
Oppenheimer have made an estimate for Aldeyra Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 12, 2020. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on December 04, 2018, representing the official price target for Aldeyra Therapeutics Inc. stock. Previously, the target price had yet another raise from $23 to $30, while Cantor Fitzgerald kept a Overweight rating on ALDX stock.
The Average True Range (ATR) for Aldeyra Therapeutics Inc. is set at 0.58 The Price to Book ratio for the last quarter was 4.25, with the Price to Cash per share for the same quarter was set at 2.27.
Trading performance analysis for ALDX stock
Aldeyra Therapeutics Inc. [ALDX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.47. With this latest performance, ALDX shares gained by 51.80% in over the last four-week period, additionally plugging by 13.64% over the last 6 months – not to mention a rise of 15.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALDX stock in for the last two-week period is set at 58.81, with the RSI for the last a single of trading hit 57.36, and the three-weeks RSI is set at 60.43 for Aldeyra Therapeutics Inc. [ALDX]. The present Moving Average for the last 50 days of trading for this stock 4.95, while it was recorded at 6.58 for the last single week of trading, and 4.72 for the last 200 days.
Aldeyra Therapeutics Inc. [ALDX]: A deeper dive into fundamental analysis
Return on Total Capital for ALDX is now -75.62, given the latest momentum, and Return on Invested Capital for the company is -81.52. Return on Equity for this stock declined to -90.31, with Return on Assets sitting at -71.28. When it comes to the capital structure of this company, Aldeyra Therapeutics Inc. [ALDX] has a Total Debt to Total Equity ratio set at 30.69. Additionally, ALDX Total Debt to Total Capital is recorded at 23.48, with Total Debt to Total Assets ending up at 19.52. Long-Term Debt to Equity for the company is recorded at 30.22, with the Long-Term Debt to Total Capital now at 23.12.
Reflecting on the efficiency of the workforce at the company, Aldeyra Therapeutics Inc. [ALDX] managed to generate an average of -$3,041,342 per employee.Aldeyra Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.80 and a Current Ratio set at 12.80.
Aldeyra Therapeutics Inc. [ALDX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Aldeyra Therapeutics Inc. posted -0.49/share EPS, while the average EPS was predicted by analysts to be reported at -0.49/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALDX.
An analysis of insider ownership at Aldeyra Therapeutics Inc. [ALDX]
There are presently around $106 million, or 62.80% of ALDX stock, in the hands of institutional investors. The top three institutional holders of ALDX stocks are: PERCEPTIVE ADVISORS LLC with ownership of 3,085,458, which is approximately 0% of the company’s market cap and around 4.90% of the total institutional ownership; PROSIGHT MANAGEMENT, LP, holding 2,035,340 shares of the stock with an approximate value of $12.88 million in ALDX stocks shares; and BLACKROCK INC., currently with $10.22 million in ALDX stock with ownership of nearly 1.866% of the company’s market capitalization.
Positions in Aldeyra Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 30 institutional holders increased their position in Aldeyra Therapeutics Inc. [NASDAQ:ALDX] by around 1,678,512 shares. Additionally, 43 investors decreased positions by around 2,635,812 shares, while 15 investors held positions by with 12,448,313 shares. The mentioned changes placed institutional holdings at 16,762,637 shares, according to the latest SEC report filing. ALDX stock had 9 new institutional investments in for a total of 222,105 shares, while 17 institutional investors sold positions of 1,270,828 shares during the same period.